FibroBiologics Announces $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Core Viewpoint - FibroBiologics, Inc. has announced a registered direct offering of 5,227,275 shares of common stock at $0.33 per share, along with a concurrent private placement of unregistered warrants for the same number of shares at the same exercise price, aiming to raise approximately $1.7 million in gross proceeds [1][3]. Group 1: Offering Details - The company will issue 5,227,275 shares of common stock at an offering price of $0.33 per share in a registered direct offering [1]. - Concurrently, unregistered warrants will be issued to purchase up to 5,227,275 shares at an exercise price of $0.33 per share, which will be exercisable upon stockholder approval [1]. - The closing of the offering is expected on or about December 16, 2025, subject to customary closing conditions [1]. Group 2: Financial Implications - The aggregate gross proceeds from the offering are expected to be approximately $1.7 million before deducting fees and expenses [3]. - If the unregistered warrants are fully exercised, additional gross proceeds of approximately $1.7 million could be realized [3]. - The net proceeds from the offering will be used for working capital and general corporate purposes [3]. Group 3: Regulatory Information - The shares offered in the registered direct offering are being made under a "shelf" registration statement that became effective on February 10, 2025 [4]. - The unregistered warrants and shares issuable upon their exercise are being offered in a private placement and have not been registered under the Securities Act [5]. Group 4: Company Overview - FibroBiologics is a clinical-stage biotechnology company focused on developing therapeutics for chronic diseases using fibroblast cells and materials, holding over 270 patents [9]. - The company is involved in various clinical pathways, including wound healing, multiple sclerosis, and cancer, representing advancements in cell therapy and tissue regeneration [9].